An expanding role for antithrombotic therapy in cancer patients

Cancer Treatment Reviews

Volumn 29, Issue SUPPL. 2, 2003, Pages 23-26

  Kakkar, Ajay K ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Antithrombotic therapy; Cancer patients; Low molecular weight heparin (LMWH); Survival; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; HEPARANASE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTEINASE;

ARTICLE; BLEEDING; BLOOD CLOTTING; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; INCIDENCE; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; PROSPECTIVE STUDY; RECURRENT DISEASE; RETROSPECTIVE STUDY; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0038206935     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)80006-3     Document Type: Article

References (22)

1. Shen V, Pollak E. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 1980; 73: 841-843.
2. Levitan N, Dowlati A, Remick S, Tahsildar H, Sivinski I, Beyth R, Rimm A. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using medicare claims data. Medicine 1999; 78: 285-291.
3. Sorensen H, Mellemkjaer L, Olsen J, Baron J. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
4. Thodiyil P, Kakkar A. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002; 87: 1076-1077.
5. Kakkar A, Haas S, Walsh D, Nash G, Encke A. Prevention of perioperative venous thromboembolism: outcome after cancer and non-cancer surgery. Thromb Haemost: 2001; XVIII Congress of ISTH Paris, Abstract OC1732.
6. Breddin H, Hach-Wunderle V, Nakov R, Kakkar V. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001; 344: 626-631.
7. Kakkar A, Kadziola Z, Breddin H, Kakkar V. Treatment of deep vein thrombosis in cancer: a comparison of unfractionated and low molecular weight heparin. Blood 2000; 96: 449A.
8. Ruf W, Mueller B. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996; 3: 379-384.
9. Taniguchi T, Kakkar A, Tuddenham E, Williamson R, Lemoine N. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 1998; 58: 4461-4467.
10. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern D, Nawroth P. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320-1327.
11. Ott I, Fischer E, Miyagi Y, Mueller B, Ruf W. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998; 140: 1241-1253.
12. Abdulkadir S, Carvalhal G, Kaleem Z, Kisiel W, Humphrey P, Catalona W, Milbrandt J. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000; 31: 443-447.
13. Yoshida E, Verrusio E, Mihara H, Oh D, Kwaan H. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res 1994; 54: 3300-3304.
14. Rudroff C, Striegler S, Schilli M, Scheele J. Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1. Eur J Surg Oncol 2001; 27: 472-476.
15. Green D, Hull R, Brant R, Pineo G. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin (letter). Lancet 1992; 339: 1476.
16. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg J. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269-277.
17. Hettiarachchi R, Smorenburg S, Ginsberg J, Levine M, Prins M, Buller H. Do heparins do more than just treat thombosis? The influence of heparins on cancer spread. Thromb Haemost 1999; 82: 947-952.
18. Gould M, Dembitzer A, Doyle R, Hastie T, Garber A. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-809.
19. Kakkar A, Kadziola Z, Williamson R, Levine M, Low V, Lemoine N. Low molecular weight heparin (LMWH) therapy and survival in advanced cancer. Blood 2002; 100: 148A.
20. Thodiyil P, Kakkar A. Can low-molecular-weight heparins improve outcome in patients with cancer? Cancer Treat Rev 2002; 28: 151-155.
21. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5: 793-802.
22. Borsig L, Wong R, Feramisco J, Nadeau D, Varki N, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci 2001; 98: 3352-3357.